Literature DB >> 31494068

Hepatocellular carcinoma, a unique tumor with a lack of biomarkers.

Jose D Debes1, Enrique Carrera2, Angelo Z Mattos3, Jhon E Prieto4, Andre Boonstra5.   

Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. Interestingly, the great majority of individuals affected by the tumor have underlying liver disease, therefore narrowing the population to be screened. Still, however, there is a clear lack of blood biomarkers, and surveillance in those at risk is performed by frequent imaging of the liver. A variety of multinational collaborations are currently invested in finding biomarkers for HCC based on liver-produced proteins. A new approach with assessment of peripheral proteins might be necessary for the successful early detection of this malignancy.
Copyright © 2019 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Biomarkers; Blood; HCC

Mesh:

Substances:

Year:  2019        PMID: 31494068     DOI: 10.1016/j.aohep.2019.07.009

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  3 in total

1.  NLRC3 High Expression Represents a Novel Predictor for Positive Overall Survival Correlated With CCL5 and CXCL9 in HCC Patients.

Authors:  Chengpan Wang; Jieyi Shi; Jietian Xu; Qiaoyu Fu; Youpeng Ding; Jessie Yang; Binbin Liu; Qiang Gao; Jie Qin; Chunmin Liang
Journal:  Front Oncol       Date:  2022-01-25       Impact factor: 6.244

2.  Hepatocellular Carcinoma: Unraveling the Role of Occult Hepatitis B Virus Infection.

Authors:  Ângelo Z Mattos; Angelo A Mattos; Jose D Debes
Journal:  Clin Gastroenterol Hepatol       Date:  2020-03-18       Impact factor: 11.382

3.  Prognostic Value and Potential Immunoregulatory Role of SCARF1 in Hepatocellular Carcinoma.

Authors:  Daniel A Patten; Alex L Wilkinson; Joanne M O'Rourke; Shishir Shetty
Journal:  Front Oncol       Date:  2020-09-29       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.